Floatz logo

gc203 til

Solid Tumor

Shanghai Juncell TherapeuticsCell therapyPhase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
59/ 100

Competitive context

479 Active assets in the Solid Tumor cohort.

Asset / SponsorPhaseRating
Irinotecan
Mirati Therapeutics Inc.
Phase 4BB
(+)-VINCRISTINE
Pfizer
Phase 4B
Atezolizumab
Hoffmann-La Roche
Phase 2/3B
Rivoceranib
Beidahuang Industry Group General Hospital
Phase 3B
Durvalumab
GlaxoSmithKline
Phase 4B

View all 50 →

Same molecule, other indications

gc203 til is also rated in:

Solid Tumors, AdultDormant
CC
Indicative ·
43 / 100
View asset →
Gynecologic CancerDormant
CC
Indicative ·
41 / 100
View asset →
Gastrointestinal CancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →